Adma Biologics (ADMA) closed the most recent trading day at $15.91, moving -1.55% from the previous trading session. The stock's performance was behind the S&P 500's daily gain of 0.49%. Meanwhile, the Dow gained 0.38%, and the Nasdaq, a tech-heavy index, added 0.72%.
Heading into today, shares of the infectious disease drug developer had lost 5.5% over the past month, lagging the Medical sector's gain of 1.93% and the S&P 500's gain of 2.99%.
The investment community will be paying close attention to the earnings performance of Adma Biologics in its upcoming release. On that day, Adma Biologics is projected to report earnings of $0.16 per share, which would represent year-over-year growth of 6.67%. Meanwhile, the latest consensus estimate predicts the revenue to be $130.1 million, indicating a 8.56% increase compared to the same quarter of the previous year.
For the full year, the Zacks Consensus Estimates project earnings of $0.57 per share and a revenue of $506.7 million, demonstrating changes of +16.33% and +18.82%, respectively, from the preceding year.
Additionally, investors should keep an eye on any recent revisions to analyst forecasts for Adma Biologics. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection remained stagnant. Adma Biologics is currently sporting a Zacks Rank of #3 (Hold).
Digging into valuation, Adma Biologics currently has a Forward P/E ratio of 28.35. This indicates a premium in contrast to its industry's Forward P/E of 20.1.
The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 99, positioning it in the top 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Remember to apply Zacks.com to follow these and more stock-moving metrics during the upcoming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ADMA Biologics Inc (ADMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
